Buparlisib

Drug Profile

Buparlisib

Alternative Names: BKM-120; BKM120-AAA; Buparlisib hydrochloride; NVP-BKM120

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Novartis; University Hospital Tubingen
  • Developer Array BioPharma; Dana-Farber Cancer Institute; Emory University; Indiana University; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (Canada); National Cancer Institute (USA); Novartis; Novartis Oncology; Ohio State University; Paoli-Calmettes-institute; Sarah Cannon Research Institute; Stanford University; University Hospital Tubingen; University of California at San Francisco
  • Class Amines; Antineoplastics; Morpholines; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Chronic lymphocytic leukaemia; CNS cancer; Glioblastoma; Haematological malignancies; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours; Thymoma
  • Phase I B cell lymphoma; Basal cell cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastrointestinal stromal tumours; Leukaemia; Mantle-cell lymphoma; Renal cell carcinoma
  • Discontinued Endometrial cancer

Most Recent Events

  • 31 Jan 2017 The Institut Paoli-Calmettes and Novartis terminate a phase Ib trial in Prostate cancer in France (NCT02487823)
  • 10 Nov 2016 Novartis terminates a phase II trial in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Switzerland, Spain, Germany, Canada, Australia, USA due to scientific and business considerations (PO) (NCT01820364)
  • 07 Oct 2016 Safety, efficacy and pharmacodynamic results from the phase II trial presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top